Natera, Inc. (NASDAQ:NTRA) CFO Sells $235,955.70 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,866 shares of the company’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $126.45, for a total value of $235,955.70. Following the sale, the chief financial officer now owns 68,851 shares in the company, valued at approximately $8,706,208.95. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $146,343.98.
• On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The shares were sold at an average price of $118.81, for a total value of $82,097.71.
• On Wednesday, October 23rd, Michael Burkes Brophy sold 496 shares of Natera stock. The shares were sold at an average price of $119.09, for a total value of $59,068.64.
• On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The shares were sold at an average price of $120.76, for a total value of $73,422.08.

Natera Stock Performance

Shares of NTRA traded up $3.20 on Friday, reaching $124.16. 1,272,197 shares of the company’s stock traded hands, compared to its average volume of 1,314,851. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The stock has a market cap of $15.36 billion, a PE ratio of -50.28 and a beta of 1.53. The stock’s 50 day simple moving average is $123.37 and its two-hundred day simple moving average is $111.99. Natera, Inc. has a 52-week low of $40.17 and a 52-week high of $133.54.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same period last year, the business posted ($0.97) earnings per share. Natera’s revenue was up 58.1% on a year-over-year basis. On average, analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

NTRA has been the topic of several recent research reports. The Goldman Sachs Group increased their price target on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a report on Friday, October 25th. TD Cowen increased their price target on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, August 9th. UBS Group cut their price target on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, Morgan Stanley increased their price target on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $125.69.

Institutional Trading of Natera

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC increased its position in Natera by 1,073.1% in the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after buying an additional 60,127 shares during the last quarter. Russell Investments Group Ltd. increased its position in Natera by 15.1% in the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after buying an additional 9,781 shares during the last quarter. Natixis purchased a new position in shares of Natera in the first quarter valued at $758,000. Baader Bank Aktiengesellschaft purchased a new position in shares of Natera in the second quarter valued at $478,000. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new position in shares of Natera in the first quarter valued at $33,956,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.